Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > COMMENTARY
COMMENTARY
-
COMMENTARY/Major Wholesalers vs Hansha Competition to Intensify on Growing Market for Generics
March 3, 2008
-
COMMENTARY/Preparations for New OTC Drug Marketing System Enter Final Stage
March 3, 2008
-
COMMENTARY/Japan Needs to Create Attractive "Stadium for Drug Discovery" and Invite Top-Level Players
February 25, 2008
-
COMMENTARY/Revision of Medical Fees May Increase Use of Drugs for Stroke, Mental Illnesses, Cancer
February 11, 2008
-
Current New Drug Development in the Japanese Pharmaceutical Industry(2)
February 11, 2008
-
Current New Drug Development in the Japanese Pharmaceutical Industry(1)
February 11, 2008
-
COMMENTARY/Generic Makers Increase Investment, but Will Consumption Really Increase as Gov't Hopes?
February 4, 2008
-
COMMENTARY/Full-Scale M&As Imminent among Dispensing Pharmacy Chains
January 28, 2008
-
COMMENTARY/Full-Scale M&As Imminent among Dispensing Pharmacy Chains
January 28, 2008
-
OPINION/The East versus West Dilemma
January 28, 2008
-
No More Need for MRs? -A Hell beyond the 2010 Crisis?-
January 14, 2008
-
COMMENTARY/Year 2007 in Retrospect
December 24, 2007
-
COMMENTARY/Appreciation Mixed with Concern: Proposed NHI Pricing Reform
December 17, 2007
-
COMMENTARY/Fight over Medical Fee/NHI Price Revision Rates Begin
December 3, 2007
-
COMMENTARY:Korosho Must Explain Its "Primary Doctor" System Proposal in Detail
October 1, 2007
-
Gakkai, Specialty Certification and Industry by Mark Colby
September 10, 2007
-
COMENTARY:Korosho Required to Cut \220 Bil. in Social Security Spending
September 3, 2007
-
COMMENTARY/NHI Drug Pricing System Reform: Many Similarities in Proposals from JPMA, PhRMA, EFPIA
August 27, 2007
-
COMMENTARY/Range of Drugs Re-priced due to Expansion of Market May Be Expanded
July 23, 2007
-
COMMENTARY/Market for Osteoporosis Drugs Booms
July 9, 2007
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…